Background: Empagliflozin is a pharmaceutical drug that is utilized in the treatment of type 2 diabetes in adult patients. The frequency of polymorphisms of UGT2B4, UGT2B7, and UGT2B15 may affect the pharmacokinetics of empagliflozin, which may have the potential to affect its safety and efficacy. Aim: The current study aimed to evaluate the possible effect of UGT2B7 genetic polymorphisms on the pharmacokinetics of empagliflozin. The study also investigated the demographic covariates that may affect empagliflozin's clearance and therapeutic effect. Results and discussion: The results showed that there was no significant correlation between age, smoking status, or measured pharmacokinetic parameters. Additionally, BMI, age, gender, and race had a small impact on empagliflozin's clearance and area under the curve (AUC), but the values were considered not clinically relevant. On the other hand, the study findings did not reveal any significant association between UGT2B7 rs7438135, rs11740316, and the measured pharmacokinetic parameters (p > 0.05), except for the MRT0-inf in the dominant model of UGT2B7 rs11740316 (p = 0.03). Conclusion: It can be concluded that the UGT2B7 polymorphism did not affect empagliflozin pharmacokinetics and had no significant effect on its clinical efficacy or therapeutic safety